Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline-Reference-Cited by-同舟云学术

Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Published:2018-12-01 Issue:34 Volume:36 Page:3411-3430
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Morgan Scott C.¹,Hoffman Karen¹,Loblaw D. Andrew¹,Buyyounouski Mark K.¹,Patton Caroline¹,Barocas Daniel¹,Bentzen Soren¹,Chang Michael¹,Efstathiou Jason¹,Greany Patrick¹,Halvorsen Per¹,Koontz Bridget F.¹,Lawton Colleen¹,Leyrer C. Marc¹,Lin Daniel¹,Ray Michael¹,Sandler Howard¹

Affiliation:

1. Scott C. Morgan, The Ottawa Hospital and University of Ottawa, Ottawa; D. Andrew Loblaw, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Karen Hoffman, MD Anderson Cancer Center, Houston, TX; Mark K. Buyyounouski, Stanford University, Stanford; Palto Alto VA Health System, Palo Alto, CA; Caroline Patton, American Society for Radiation Oncology, Arlington, VA; Daniel Barocas, Vanderbilt University Medical Center, Nashville, TN; Soren Bentzen, University of Maryland...

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.18.01097

Reference103 articles.

1. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

2. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial

3. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial

4. Image-Guided Radiotherapy for Localized Prostate Cancer: Treating a Moving Target

5. Dose-Fractionation Sensitivity of Prostate Cancer Deduced From Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: α/β = 1.4 (0.9–2.2) Gy

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Outcomes Following Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy in High-Risk Prostate Cancer: Update From the FASTR/FASTR-2 Trials;Practical Radiation Oncology;2024-01

2. Radiation therapy;Penn Clinical Manual of Urology;2024

3. Long term update on toxicity and survival of a phase II trial of linac‐based stereotactic body radiation therapy for low‐intermediate risk prostate cancer;The Prostate;2023-12-19

4. Evaluation of Patients for Radiotherapy for Prostate Adenocarcinoma;Radiation Therapy;2023-11-08

5. The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer—Quo Vadimus?;World Journal of Urology;2023-11-03